Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone
    3.
    发明授权
    Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone 失效
    3,4-二羟基-1-环戊基嘌呤酮的合成

    公开(公告)号:US5329008A

    公开(公告)日:1994-07-12

    申请号:US44339

    申请日:1993-04-07

    CPC分类号: C07D473/00

    摘要: Synthesis of the triol of the following formula (I) from an alcohol of the formula (IV): ##STR1## via steps including protecting and then cyanating the alcohol to yield a cyanide, isomerization of the double bond, hydrolysis followed by reduction of the cyanide back to an alcohol and cis-dihydroxylation of the double bond.

    摘要翻译: 通过步骤包括保护然后使醇氰化以产生氰化物,从式(IV)的醇中合成下式(I)的三醇: 双键,水解,然后将氰化物还原成醇,双键顺式 - 二羟基化。

    Kinetic resolution of pyridazinones using lipase
    5.
    发明授权
    Kinetic resolution of pyridazinones using lipase 失效
    使用脂肪酶的哒嗪酮的动力学拆分

    公开(公告)号:US5053338A

    公开(公告)日:1991-10-01

    申请号:US560941

    申请日:1990-07-20

    IPC分类号: C07D237/04

    CPC分类号: C07D237/04

    摘要: A kinetic resolution of pyridazinones of the following formula (A): ##STR1## where R.sup.1 is alkyl by enzymatic hydrolysis results in good optical purity of the phenolic product. This is significant considering the distance in the molecule (A) from the C-5 chiral center to the site of hydrolysis.

    摘要翻译: 下式(A)的哒嗪酮的动力学拆分:其中R1是通过酶水解的烷基导致酚产物的良好的光学纯度。 考虑到分子(A)从C-5手性中心到水解位点的距离是重要的。

    A1 adenosine receptor antagonists
    6.
    发明授权
    A1 adenosine receptor antagonists 有权
    A1腺苷受体拮抗剂

    公开(公告)号:US07247639B2

    公开(公告)日:2007-07-24

    申请号:US10861677

    申请日:2004-06-04

    CPC分类号: C07D473/04 C07D473/06

    摘要: The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceutically acceptable carrier are further provided. Compositions also include diagnostic assay-type probes comprising a novel A1 adenosine receptor antagonist of formula (I) that is labeled or conjugated with radioactive or non-radioactive material. Methods for treating A1 adenosine receptor related disorders comprising administering an A1 adenosine receptor antagonist of formula (I) are also disclosed. The novel A1 adenosine receptor antagonist compositions of formula (I) find further use in diagnostic and imaging methods. wherein R3 is Alk14ArR16, and wherein Alk14 is C1-8 straight or branched alkylene or alkenylene.

    摘要翻译: 本发明提供新颖的腺苷受体拮抗剂,更具体地,提供式(I)的Aβ1腺苷受体拮抗剂。 进一步提供了包含式(I)的A 1 +腺苷受体拮抗剂和药学上可接受的载体的药物组合物。 组合物还包括诊断测定型探针,其包含用放射性或非放射性物质标记或缀合的式(I)的新的A 1 N 2腺苷受体拮抗剂。 还公开了治疗A 1 N 2腺苷受体相关病症的方法,其包括施用式(I)的Aβ1 N 2腺苷受体拮抗剂。 式(I)的新型A 1 N 1腺苷受体拮抗剂组合物进一步用于诊断和成像方法。 其中R 3是Alk 14 ArR 16,并且其中Alk 14是C 1-8烷基, / SUB>直链或支链亚烷基或亚烯基。